Investor
GILEAD SCIENCES, INC.
CIK 0000882095 · filed 2026-05-08 · SEC filing
13F book
$2.12B
Positions
6
Largest name
36.4%
Arcellx Inc
Est. mark
$187.7M
Price effect on 6 names still held. Flow −$5.41M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Arcellx Inc | — | 6.72M | $771.7M | 36.4% | $333.5M | Held |
| Arcus Biosciences, Inc. | RCUS | 31.4M | $678.8M | 32.1% | −$70.1M | Held |
| Galapagos Nv | — | 16.7M | $501.2M | 23.7% | −$49.4M | Held |
| Assembly Biosciences, Inc. | ASMB | 4.51M | $125M | 5.9% | −$28.2M | Held |
| Kyverna Therapeutics, Inc. | KYTX | 4.13M | $35.6M | 1.7% | −$3.18M | Held |
| Xilio Therapeutics, Inc. | XLO | 650.4K | $5.47M | 0.3% | $5.05M | Cut−$359.5K |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.